In a filing, Beam Therapeutics Inc revealed its CEO Evans John M. unloaded Company’s shares for reported $0.8 million on Jan 30 ’25. In the deal valued at $26.75 per share,30,000 shares were sold. As a result of this transaction, Evans John M. now holds 908,659 shares worth roughly $23.4 million.
Then, JOHN M EVANS bought 30,000 shares, generating $802,482 in total proceeds.
Before that, Bellon Christine sold 1,241 shares. Beam Therapeutics Inc shares valued at $30,628 were divested by the Chief Legal Officer at a price of $24.68 per share. As a result of the transaction, Bellon Christine now holds 102,968 shares, worth roughly $2.65 million.
Cantor Fitzgerald upgraded its Beam Therapeutics Inc [BEAM] rating to an Overweight from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who increased its forecast for the stock in early November from “a Market perform” to “an Outperform”. Scotiabank began covering BEAM with “Sector outperform” recommendation on October 16, 2024. H.C. Wainwright started covering the stock on July 23, 2024. It rated BEAM as “a Buy”.
Price Performance Review of BEAM
On Tuesday, Beam Therapeutics Inc [NASDAQ:BEAM] saw its stock jump 0.63% to $25.75. Over the last five days, the stock has gained 1.94%. Beam Therapeutics Inc shares have risen nearly 3.83% since the year began. Nevertheless, the stocks have fallen -2.57% over the past one year. While a 52-week high of $49.50 was reached on 01/07/25, a 52-week low of $20.84 was recorded on 01/15/25. SMA at 50 days reached $26.37, while 200 days put it at $25.15.
Levels Of Support And Resistance For BEAM Stock
The 24-hour chart illustrates a support level at 25.11, which if violated will result in even more drops to 24.48. On the upside, there is a resistance level at 26.36. A further resistance level may holdings at 26.98. The Relative Strength Index (RSI) on the 14-day chart is 49.43, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.39, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 40.59%. Stochastics %K at 59.48% indicates the stock is a holding.
How much short interest is there in Beam Therapeutics Inc?
A steep rise in short interest was recorded in Beam Therapeutics Inc stocks on 2025-01-15, growing by 0.73 million shares to a total of 10.79 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 10.06 million shares. There was a rise of 6.76%, which implies that there is a positive sentiment for the stock.
